The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05598333
Recruitment Status : Recruiting
First Posted : October 28, 2022
Last Update Posted : May 6, 2024
Information provided by (Responsible Party):
Asklepios Biopharmaceutical, Inc.

Brief Summary:

This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age >18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF.

Subjects will be randomized into one of three treatment groups in a 1:1:1

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Drug: AB-1002 Phase 2

Detailed Description:

Subjects will be randomized into one of three treatment groups in a 1:1:1 fashion to either 3.25E13vg (n=30-50), 6.5E13 (n=30-50) or placebo group (n=30-50).

Approximately 90 to 150 subjects will be randomly assigned to study intervention Placebo

Study duration until the primary analysis at 52 week will be approximately 37 months including 25 months of recruitment and 52-week Observation Period after dosing. Once all the subjects complete the 52 weeks Observation Period, the treatment groups will be unblinded and primary analysis performed. Study participation duration: The study will last 52 weeks from dosing, with another 4 years of long-term follow-up for a total of 5 years. During the 4 year long-term follow up sites will contact subjects twice a year for two years, then once a year for the remaining two years for safety, efficacy assessments, and survival

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Adaptive, double blinded, placebo controlled, randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The IWRS will be programmed with blind-breaking instructions. In case of an emergency, the investigator has the responsibility for determining if unblinding of a subject's intervention assignment is warranted. If the investigator is unavailable, and a treating physician not associated with the study requests emergency unblinding, the emergency unblinding requests are forwarded to the emergency medical advice 24 hours/7 day service.
Primary Purpose: Treatment
Official Title: A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy
Actual Study Start Date : October 20, 2023
Estimated Primary Completion Date : December 2030
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AB-1002

Randomized in 1:1:1 into one of three groups.

Group 1: 3.25E13vg (n=30-50)

Drug: AB-1002
Intracoronary Infusion of AB-1002 or placebo
Other Names:
  • Gene Therapy
  • NAN-101

Experimental: Treatment Group 2 AB-1002

Randomized in 1:1:1 into one of three groups.

Group 2: 6.5E13vg (n=30-50)

Drug: AB-1002
Intracoronary Infusion of AB-1002 or placebo
Other Names:
  • Gene Therapy
  • NAN-101

Placebo Comparator: Treatment Group 3

Randomized in 1:1:1 into one of three groups.

Group 3: Placebo (n=30-50)

Drug: AB-1002
Intracoronary Infusion of AB-1002 or placebo
Other Names:
  • Gene Therapy
  • NAN-101

Primary Outcome Measures :
  1. Cardiovascular Related Death [ Time Frame: 52 weeks ]
  2. NYHA Classification [ Time Frame: 52 weeks ]
    NYHA Classification Change from baseline

  3. Left Ventricular Ejection Fraction [ Time Frame: 52 weeks ]
    LVEF change from baseline

  4. Peak Oxygen Update (VO2) [ Time Frame: 52 weeks ]
    VO2 change from baseline

  5. Six Minute Walk Test [ Time Frame: 52 weeks ]
    6MWT distance change from baseline

Secondary Outcome Measures :
  1. Heart Failure Related Hospitalizations [ Time Frame: 52 weeks ]
    Number of hospitalizations attributed to heart failure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject must be age ≥18 years of age, at the time of signing the informed consent.
  2. Chronic non-ischemic cardiomyopathy
  3. 15% ≤ LVEF ≤ 35% by transthoracic echocardiography (TTE) at screening
  4. 6MWT >50 meters
  5. Medically stable, NYHA Class III HF for a minimum of 4 weeks while on appropriate medical therapy (defined below) including, but not limited to:

    1. Beta blocker therapy and ACE inhibitor or angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy (Entresto) for ≥ 90 days prior to enrollment.

      May also receive aldosterone antagonist therapy. Doses of the above medications must be stable for ≥ 30 days prior to enrollment; and

    2. Cardiac resynchronization therapy (Zareba et al 2011), if clinically indicated, must have been implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment.
  6. Women of childbearing potential must use at least one of the following acceptable birth control methods throughout the study and for 6 months after IP administration:

    • Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to IP administration
    • Intrauterine device in place for at least 90 days prior to receiving IP
    • Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior to receiving IP
    • Abstinence (the subject must be willing to remain abstinent from screening to 6 months after receiving IP). Females are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
    • Surgical sterilization of the partner(s) (vasectomy) for >180 days prior to IP administration
    • Hormonal contraceptives starting > 90 days prior to IP. If hormonal contraceptives are started less than 90 days prior to receiving IP, subjects must agree to use a barrier method (diaphragm plus spermicide or condom) from screening through 90 days after initiation of hormonal contraceptives
  7. Males subjects capable of fathering a child:

    • Must agree to use a condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant from IP administration through 6 months after the time of IP administration
    • Must agree not to donate sperm for 6 months after time of receiving IP
    • Documented evidence of vasectomy in males for 180 days minimum prior to receiving IP is an acceptable form of contraception
    • Males who claim abstinence as their method of contraception are allowed, provided they agree to use barrier methods should they become sexually active from screening through 6 months after receiving IP. Males are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
  8. Appropriate candidate for protocol-specified intracoronary infusion in the judgment of the infusing interventional cardiologist

    Exclusion Criteria:

    Subjects are excluded from the study if any of the following criteria apply:

  9. Chronic ischemic cardiomyopathy secondary to obstructive coronary artery disease
  10. Intravenous (IV) inotropic therapy, intra-aortic balloon pump (IABP) or percutaneous cardiac assist device therapy within 30 days prior to enrollment
  11. Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic LV aneurysm
  12. Cardiac surgery or percutaneous coronary intervention (PCI) within 30 days prior to screening
  13. Uncorrected Third degree heart block
  14. Clinically significant myocardial infarction (MI) in the judgment of the subject's physician (e.g., ST elevation MI [STEMI] or large non-STEMI) within 6 months prior to enrollment
  15. Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), surgically implanted LVAD or cardiac shunt
  16. Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LV reduction surgery, heart transplant, conventional revascularization procedure, or valvular repair within 3 months of IP dosing in judgement of investigator.
  17. Known hypersensitivity to contrast dyes (not easily controlled by antihistamines) used for angiography; history of, or likely need for, high-dose steroid pretreatment prior to contrast angiography.
  18. Expected survival < 1 year in the judgment of the investigator
  19. Active or suspected infection within 48 hours prior to intra-coronary infusion as evidenced by fever or positive culture
  20. Known intrinsic liver disease (e.g., cirrhosis, hepatitis A, chronic hepatitis B or hepatitis C virus infection). If serology is positive and PCR is known to be negative, subject may be eligible (confirm with medical monitor).
  21. Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase) > 2x upper limit of normal (ULN) within 30 days prior to enrollment.
  22. Chronic Kidney Disease Stage 5, dialysis dependent or eGFR<15 within 30 days prior to enrollment
  23. Bleeding diathesis or thrombocytopenia defined as platelets <50,000 platelets/μL within 30 days prior to enrollment
  24. Anemia defined as hemoglobin <10 g/dL or transfusion dependent within 30 days prior to enrollment
  25. Neutropenia defined as absolute neutrophils <1500 mm3 within 30 days prior to enrollment
  26. Known AIDS or HIV-positive status, or a previous diagnosis of immunodeficiency with an absolute neutrophil count <1000 cells/mm3
  27. Previous participation in a study of gene transfer
  28. Receiving investigational intervention or participating in another clinical study within 30 days of another investigational drug administration prior to administration of AB-1002 that may impact the therapeutic potential of AB-1002.
  29. Pregnancy or breastfeeding or plans to become pregnant within the next 12 months at the time of screening
  30. Subjects with any other condition which in the opinion of the investigator would preclude participation in the study (including risk for non-compliance and any intercurrent conditions that pose an undue medical hazard, or which could interfere with the interpretation of the study results)
  31. Malignant neoplasm within 5 years of dosing, with the exception of those with negligible risk of metastasis or death (such as adequately treated carcinoma in situs of the cervix, basal or squamous cell skin cancer, localized prostate cancer or ductal carcinoma in situ)
  32. Any documented history of non-compliance with medications, illicit drug use or laboratory evidence of illicit drug use during screen period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05598333

Layout table for location contacts
Contact: Medical Affairs (919) 561-6210

Layout table for location information
United States, Minnesota
Minneapolis Heart Institute Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Pamela Morley    612-863-6066   
Principal Investigator: Jay Traverse, MD         
United States, Ohio
The Christ Hospital / The Linder Center for Research Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Michael Weber    513-585-1777   
Principal Investigator: Timothy Henry         
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Elias Shamieh    513-558-3016   
Principal Investigator: Ahmad Saad, MD         
Sponsors and Collaborators
Asklepios Biopharmaceutical, Inc.
Layout table for additonal information
Responsible Party: Asklepios Biopharmaceutical, Inc. Identifier: NCT05598333    
Other Study ID Numbers: ASK-CHF2-CS201
First Posted: October 28, 2022    Key Record Dates
Last Update Posted: May 6, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No data will be shared with researchers outside of AskBio

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases